Clinical characteristics, diagnosis, and treatment of 40 cases of venous thrombotic disease in children at a single center

Qian LI, Fei-Qiu WEN, Ying WANG, Gui-Chi ZHOU, Yu-Cong ZHANG, Long-Wei SUN, Zhi-Hui LI, Gan XIE, Xiao-Ying FU, Xue FENG, Rong-Bo LIN, Li CHEN, Lin LIU, Dong-Fang CHE, Zhen-Feng LI, Zhen-Jiang LIANG, Li-Xiang ZHU, Feng WEI

Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (8) : 966-971.

PDF(654 KB)
HTML
PDF(654 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (8) : 966-971. DOI: 10.7499/j.issn.1008-8830.2511078
CLINICAL RESEARCH

Clinical characteristics, diagnosis, and treatment of 40 cases of venous thrombotic disease in children at a single center

Author information +
History +

Abstract

Objective To investigate the clinical characteristics, diagnostic approach, multidisciplinary diagnosis and treatment model, and anticoagulation strategies of venous thrombotic disease in children, summarize diagnosis and treatment experience, and provide a reference for improving standardized management of this condition. Methods A retrospective analysis was conducted on clinical data of 40 children with venous thrombotic disease managed by the multidisciplinary team (MDT) at Shenzhen Children's Hospital. Data included demographic characteristics, underlying diseases, risk factors, clinical manifestations, diagnostic procedures, anticoagulation regimens, and clinical outcomes. Results Among the 40 children, the most common risk factor was central venous catheter placement (42%), and the most frequent underlying diseases were malignant tumors (30%) and severe infections (25%). Clinical manifestations were diverse and often insidious, frequently masked by primary diseases. All cases were confirmed by imaging examinations. Anticoagulation mainly involved low-molecular-weight heparin and warfarin, with some patients receiving oral anticoagulants. Following MDT management and individualized anticoagulation therapy, the overall recanalization rate was 98%, the incidence of bleeding was 5%, and no major bleeding events occurred. Conclusions Venous thrombotic disease in children commonly occurs secondary to severe underlying conditions and presents with atypical clinical features, requiring increased diagnostic vigilance. A diagnosis and treatment model centered on an MDT, combined with individualized anticoagulation therapy, effectively improves prognosis and represents an effective strategy for managing these complex cases.

Key words

Venous thrombotic disease / Multidisciplinary team / Anticoagulant therapy / Child

Cite this article

Download Citations
Qian LI , Fei-Qiu WEN , Ying WANG , et al . Clinical characteristics, diagnosis, and treatment of 40 cases of venous thrombotic disease in children at a single center[J]. Chinese Journal of Contemporary Pediatrics. 2026, 28(8): 966-971 https://doi.org/10.7499/j.issn.1008-8830.2511078

References

[1]
O'Brien SH, Stanek JR, Witmer CM, et al. The continued rise of venous thromboembolism across US children's hospitals[J]. Pediatrics, 2022, 149(3): e2021054649. DOI: 10.1542/peds.2021-054649 .
[2]
Jaffray J, Mahajerin A, Branchford B, et al. A new risk assessment model for hospital-acquired venous thromboembolism in critically ill children: a report from the children's hospital-acquired thrombosis consortium[J]. Pediatr Crit Care Med, 2022, 23(1): e1-e9. PMCID: PMC8738123. DOI: 10.1097/PCC.0000000000002826 .
[3]
Citla Sridhar D, Abou-Ismail MY, Ahuja SP. Central venous catheter-related thrombosis in children and adults[J]. Thromb Res, 2020, 187: 103-112. DOI: 10.1016/j.thromres.2020.01.017 .
[4]
Sochet AA, Kiskaddon A, Betensky M, et al. Venous thromboembolism among critically ill children: a narrative review[J]. Semin Thromb Hemost, 2021, 47(6): 631-642. DOI: 10.1055/s-0041-1722847 .
[5]
Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism[J]. Blood Adv, 2018, 2(22): 3292-3316. PMCID: PMC6258911. DOI: 10.1182/bloodadvances.2018024786 .
[6]
Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness[J]. J Thromb Haemost, 2020, 18(11): 3099-3105. PMCID: PMC9906345. DOI: 10.1111/jth.15073 .
[7]
Monagle P, Azzam M, Bercovitz R, et al. American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients[J]. Blood Adv, 2025, 9(10): 2587-2636. PMCID: PMC12235321. DOI: 10.1182/bloodadvances.2024015328 .
[8]
Daei M, Abbasi G, Khalili H, et al. Direct oral anticoagulants toxicity in children: an overview and practical guide[J]. Expert Opin Drug Saf, 2022, 21(9): 1183-1192. DOI: 10.1080/14740338.2022.2110236 .
[9]
Spencer NH, Sardo LA, Cordell JP, et al. Structure and function of a perioperative anticoagulation management clinic[J]. Thromb Res, 2019, 182: 167-174. DOI: 10.1016/j.thromres.2019.08.007 .
[10]
Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia[J]. Blood Adv, 2018, 2(22): 3360-3392. PMCID: PMC6258919. DOI: 10.1182/bloodadvances.2018024489 .
[11]
Kahn SR, Hirsch AM, Akaberi A, et al. Functional and exercise limitations after a first episode of pulmonary embolism: results of the ELOPE prospective cohort study[J]. Chest, 2017, 151(5): 1058-1068. DOI: 10.1016/j.chest.2016.11.030 .
[12]
Jaffray J, Witmer C, O'Brien SH, et al. Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children[J]. Blood, 2020, 135(3): 220-226. PMID: 31909784 DOI: 10.1182/blood.2019002260 .
[13]
Saposnik G, Barinagarrementeria F, Brown RD, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2011, 42(4): 1158-1192. DOI: 10.1161/STR.0b013e31820a8364 .
[14]
Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 ): e737S-e801S. PMCID: PMC3278066. DOI: 10.1378/chest.11-2308 .
Suppl
[15]
Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI: atheromatous affection of arteries. 1858[J]. Nutr Rev, 1989, 47(1): 23-25. DOI: 10.1111/j.1753-4887.1989.tb02747.x .
[16]
Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial[J]. Lancet Haematol, 2020, 7(1): e18-e27. DOI: 10.1016/S2352-3026(19)30219-4 .
[17]
Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis[J]. Lancet, 2012, 379(9828): 1835-1846. DOI: 10.1016/S0140-6736(11)61904-1 .
[18]
Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer[J]. J Am Coll Cardiol, 2017, 70(19): 2411-2420. DOI: 10.1016/j.jacc.2017.09.024 .

Footnotes

所有作者均声明无利益冲突。

PDF(654 KB)
HTML

Accesses

Citation

Detail

Sections
Recommended

/